Vincerx Pharma Inc
NASDAQ:VINC
Operating Margin
Vincerx Pharma Inc
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Operating Margin Across Competitors
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| US |
|
Vincerx Pharma Inc
NASDAQ:VINC
|
282.4k USD | N/A | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
-17 527%
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
327.6B USD |
30%
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
155.7B USD |
25%
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
134.5B USD |
38%
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
115.2B USD |
38%
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
-370%
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
116.4B AUD |
26%
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
55.6B USD |
29%
|
|
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR |
-33%
|
|
| US |
|
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
|
40.7B USD |
-5%
|
Vincerx Pharma Inc
Glance View
Vincerx Pharma, Inc. operates as a clinical-stage biopharmaceutical company which develops antibody drugs. The company is headquartered in Palo Alto, California and currently employs 56 full-time employees. The company went IPO on 2020-03-10. The Company’s small molecule drug program includes VIP152, which is a highly selective, clinical-stage positive transcription elongation factor-beta/cyclin-dependent kinase 9 (PTEFb/CDK9) inhibitor. The firm's antibody-drug conjugate (ADC) platform includes VIP943 (targeting CD123) and VIP924 (targeting CXCR5), which are ADC compounds addressing known and novel oncology targets. The Company’s bioconjugation program also includes VIP236, which is a small molecule drug conjugate (SMDC) for solid tumors.
See Also
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Based on Vincerx Pharma Inc's most recent financial statements, the company has Operating Margin of 0%.
You don't have any saved screeners yet